Published in J Autoimmun on May 01, 2003
Genes, autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol (2011) 1.17
B- and T-cell responses in group a streptococcus M-protein- or Peptide-induced experimental carditis. Infect Immun (2009) 0.94
Animal models to investigate the pathogenesis of rheumatic heart disease. Front Pediatr (2014) 0.88
Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol (2014) 0.83
Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination. AAPS J (2014) 0.83
Identification of streptococcal m-protein cardiopathogenic epitopes in experimental autoimmune valvulitis. J Cardiovasc Transl Res (2013) 0.83
An animal model of chronic rheumatic valvulitis induced by formalin-killed streptococci. Rheumatol Int (2009) 0.81
Repeat exposure to group A streptococcal M protein exacerbates cardiac damage in a rat model of rheumatic heart disease. Autoimmunity (2016) 0.76
Autoimmune valvular carditis. Curr Allergy Asthma Rep (2015) 0.75
Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate. Hum Vaccin Immunother (2016) 0.75
Serum Levels of IL-17 and IL-23 in Patients With Rheumatic Mitral Stenosis. Medicine (Baltimore) (2016) 0.75
Towards developing a vaccine for rheumatic heart disease. Glob Cardiol Sci Pract (2017) 0.75
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet (2002) 3.21
Nasal-associated lymphoid tissue and olfactory epithelium as portals of entry for Burkholderia pseudomallei in murine melioidosis. J Infect Dis (2009) 2.23
Malaria vaccine developments. Lancet (2004) 1.77
A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol (2007) 1.67
Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral malaria. J Immunol (2010) 1.65
Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. J Immunol (2005) 1.56
Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol (2002) 1.51
The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection. J Exp Med (2002) 1.48
A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int J Antimicrob Agents (2002) 1.45
Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis (2003) 1.26
Route of infection in melioidosis. Emerg Infect Dis (2005) 1.25
Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect Immun (2005) 1.25
Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. J Immunol (2002) 1.19
Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology (2015) 1.17
Clinical presentation of melioidosis in Queensland, Australia. Trans R Soc Trop Med Hyg (2005) 1.14
What really happens to dendritic cells during malaria? Nat Rev Microbiol (2008) 1.14
Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol Med Microbiol (2007) 1.14
Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog (2007) 1.12
M protein typing of Thai group A streptococcal isolates by PCR-Restriction fragment length polymorphism analysis. BMC Microbiol (2005) 1.10
Whole parasite blood stage malaria vaccines: a convergence of evidence. Hum Vaccin (2010) 1.09
High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis (2004) 1.08
emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol (2009) 1.06
Comparison of routine bench and molecular diagnostic methods in identification of Burkholderia pseudomallei. J Clin Microbiol (2009) 1.06
Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation (2005) 1.06
Prospective surveillance of streptococcal sore throat in a tropical country. Pediatr Infect Dis J (2009) 1.06
Demonstration of a cell-mediated immune response in melioidosis. J Infect Dis (2002) 1.06
Brucellosis in northern Australia. Am J Trop Med Hyg (2010) 1.05
Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. J Clin Invest (2010) 1.05
Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater (2012) 1.01
Prospective surveillance of invasive group a streptococcal disease, Fiji, 2005-2007. Emerg Infect Dis (2009) 1.01
The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc Natl Acad Sci U S A (2003) 1.01
A case for whole-parasite malaria vaccines. Int J Parasitol (2007) 0.99
Clinical presentation of rheumatic fever in an endemic area. Arch Dis Child (2009) 0.99
Rodent blood-stage Plasmodium survive in dendritic cells that infect naive mice. Proc Natl Acad Sci U S A (2011) 0.98
Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes. Microbes Infect (2011) 0.98
Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help. J Immunol (2013) 0.98
Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One (2009) 0.97
Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines (2010) 0.96
Systemic tumor necrosis factor generated during lethal Plasmodium infections impairs dendritic cell function. J Immunol (2007) 0.95
Interactions between malaria parasites and the host immune system. Curr Opin Immunol (2005) 0.95
M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol (2005) 0.94
Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew Chem Int Ed Engl (2010) 0.94
Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem (2007) 0.94
Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J Exp Med (2013) 0.94
B- and T-cell responses in group a streptococcus M-protein- or Peptide-induced experimental carditis. Infect Immun (2009) 0.94
Clinical features that affect indirect-hemagglutination-assay responses to Burkholderia pseudomallei. Clin Vaccine Immunol (2009) 0.93
Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis (2005) 0.93
What have we learnt from mouse models for the study of malaria? Eur J Immunol (2009) 0.92
CD8+ T lymphocyte-mediated loss of marginal metallophilic macrophages following infection with Plasmodium chabaudi chabaudi AS. J Immunol (2006) 0.92
Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg Med Chem (2008) 0.92
Impaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity. Infect Immun (2012) 0.91
Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1. Infect Immun (2002) 0.91
A model of immunity to Burkholderia pseudomallei: unique responses following immunization and acute lethal infection. Microbes Infect (2005) 0.91
Escaping the immune system: How the malaria parasite makes vaccine development a challenge. Trends Parasitol (2013) 0.89
Susceptibility to Burkholderia pseudomallei is associated with host immune responses involving tumor necrosis factor receptor-1 (TNFR1) and TNF receptor-2 (TNFR2). FEMS Immunol Med Microbiol (2008) 0.89
Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J Infect Dis (2006) 0.89
Low-level Plasmodium falciparum blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers. J Infect Dis (2012) 0.89
Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Hum Vaccin Immunother (2012) 0.88
Regulation of Toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases. Mol Immunol (2010) 0.88
Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol Cell Biol (2007) 0.88
Cross-species malaria immunity induced by chemically attenuated parasites. J Clin Invest (2013) 0.88
Impact of streptozotocin-induced diabetes on functional responses of dendritic cells and macrophages towards Burkholderia pseudomallei. FEMS Immunol Med Microbiol (2011) 0.88
The effect of different Burkholderia pseudomallei isolates of varying levels of virulence on toll-like-receptor expression. Trans R Soc Trop Med Hyg (2008) 0.87
Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship. PLoS One (2012) 0.87
A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun (2002) 0.87
Effect of cryopreservation on the immunogenicity of umbilical cord blood cells. Transfus Apher Sci (2004) 0.86
Evaluation of recombinant antigens for diagnosis of melioidosis. FEMS Immunol Med Microbiol (2008) 0.86
Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine. Infect Immun (2008) 0.86
Analysis of circumsporozoite protein-specific immune responses following recent infection with Plasmodium vivax. Am J Trop Med Hyg (2004) 0.86
Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity. Infect Immun (2012) 0.86
Neutrophil labeling with [(99m)Tc]-technetium stannous colloid is complement receptor 3-mediated and increases the neutrophil priming response to lipopolysaccharide. Nucl Med Biol (2006) 0.86
Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun (2003) 0.85
Malaria vaccines: the case for a whole-organism approach. Expert Opin Biol Ther (2008) 0.85
Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci (2003) 0.85
A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine (2011) 0.85
Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease. Immunol Res (2006) 0.84
Cardiac myosin epitopes for monitoring progression of rheumatic fever. Pediatr Infect Dis J (2011) 0.84
Presence of fibronectin-binding protein gene prtF2 in invasive group A streptococci in tropical Australia is associated with increased internalisation efficiency. Microbes Infect (2005) 0.84
Vaccination against rheumatic heart disease: a review of current research strategies and challenges. Curr Infect Dis Rep (2012) 0.84
Polymer encapsulation of magnesium to control biodegradability and biocompatibility. J Nanosci Nanotechnol (2014) 0.84
Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model. Int J Antimicrob Agents (2006) 0.84
Determination of Coxiella burnetii seroprevalence in macropods in Australia. Vet Microbiol (2011) 0.84
Dual stimulation of MyD88-dependent Toll-like receptors induces synergistically enhanced production of inflammatory cytokines in murine bone marrow-derived dendritic cells. J Infect Dis (2010) 0.83
Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. J Med Chem (2010) 0.83
Immune response to superoxide dismutase in group A streptococcal infection. FEMS Immunol Med Microbiol (2004) 0.83
Dendritic cell biology during malaria. Cell Microbiol (2007) 0.82
Oral vaccine delivery--new strategies and technologies. Curr Drug Deliv (2009) 0.82
Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea. Am J Trop Med Hyg (2005) 0.82
Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine (2007) 0.82
Seropositivity to Burkholderia pseudomallei does not reflect the development of cell-mediated immunity. Trans R Soc Trop Med Hyg (2008) 0.81
Expression of maturation markers on murine dendritic cells in response to group A streptococcal lipopeptide vaccines. Vaccine (2009) 0.81